Movement Disorders USMLE Step 1 Practice Question
A 65-year-old man with Parkinson disease for 8 years presents with wearing-off symptoms appearing 2 hours before his next levodopa dose. Vitals: BP 128/76, HR 82, RR 16, Temp 37°C, SpO2 98%. Recent MRI brain shows no structural lesions. He denies dyskinesias. His neurologist adds entacapone to his regimen. Which of the following best describes the mechanism of action of this added medication?
Answer choices
- AIrreversible inhibition of dopamine receptors
- BStimulation of NMDA receptors in the basal ganglia
- CInhibition of GABA transaminase to increase striatal GABA
- DBlockade of muscarinic receptors in the periphery only
- EInhibition of catechol-O-methyltransferase to decrease levodopa metabolismCorrect answer
- FIrreversible MAO-B inhibition
See the full explanation
Get the correct-answer rationale, why each distractor is wrong, the underlying mechanism, and high-yield associations — plus adaptive practice that targets your weak areas — with a free MedBoardPRO account.